EMA Authorised: Tenkasi (previously Orbactiv) (oritavancin (diphosphate)) — Menarini International Operations Luxembourg S.A.

View source ↗

Summary

EMA has authorised Tenkasi (oritavancin diphosphate) for soft tissue infections and bacterial skin diseases, expanding therapeutic options.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Skin Diseases
• Soft Tissue Infections

Drugs mentioned

• Tenkasi (oritavancin (diphosphate))

Snippet

Status: Authorised. Therapeutic area: Soft Tissue Infections;Skin Diseases, Bacterial. MAH: Menarini International Operations Luxembourg S.A.. Decision date: 19/11/2024